Literature DB >> 14552502

Risk adjustment in studies using administrative data.

Michael J Sernyak1, Robert Rosenheck.   

Abstract

Administrative data are increasingly used to evaluate service use and cost of treatments in "real world" settings. However, the degree to which administrative data can be used to risk-adjust for differences between nonrandomized groups receiving different treatments has not been studied. This study used data from a large randomized trial to determine whether administrative data describing previous utilization and cost are as good as clinical data in predicting future resource utilization and cost. Clinical data (symptoms, quality of life, pharmacological side effects) and administrative data (inpatient utilization and total cost) were obtained from a large randomized clinical trial comparing clozapine and haloperidol. The combination of administrative measures prior to randomization was the best predictor in a multiple regression model of service use in the year after randomization (adjusted r2 = 0.27-0.31). Models using administrative data alone predicted 24 to 28 percent of the variance of service use and costs, while clinical data predicted only 6 to 7 percent of the variation in the same dependent variables. In this analysis, administrative data about previous utilization and costs were far more successful than clinical data alone at predicting future utilization and costs and are therefore likely to be better risk adjusters in studies with nonrandomized comparison groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552502     DOI: 10.1093/oxfordjournals.schbul.a007003

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  5 in total

1.  Psychological Research With Administrative Data Sets: An Underutilized Strategy for Mental Health Services Research.

Authors:  James T Walkup; Philip T Yanos
Journal:  Prof Psychol Res Pr       Date:  2005-10

2.  The effect of complementary and alternative medicine claims on risk adjustment.

Authors:  Bonnie K Lind; Chad Abrams; William E Lafferty; Paula K Diehr; David E Grembowski
Journal:  Med Care       Date:  2006-12       Impact factor: 2.983

3.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19

4.  An in-depth assessment of a diagnosis-based risk adjustment model based on national health insurance claims: the application of the Johns Hopkins Adjusted Clinical Group case-mix system in Taiwan.

Authors:  Hsien-Yen Chang; Jonathan P Weiner
Journal:  BMC Med       Date:  2010-01-18       Impact factor: 8.775

5.  Costs of treating patients with schizophrenia who have illness-related crisis events.

Authors:  Baojin Zhu; Haya Ascher-Svanum; Douglas E Faries; Xiaomei Peng; David Salkever; Eric P Slade
Journal:  BMC Psychiatry       Date:  2008-08-26       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.